Provided by Tiger Trade Technology Pte. Ltd.

VolitionRX

0.2527
+0.00672.72%
Volume:880.22K
Turnover:219.88K
Market Cap:31.03M
PE:-1.10
High:0.2578
Open:0.2467
Low:0.2410
Close:0.2460
52wk High:0.9400
52wk Low:0.2200
Shares:122.80M
Float Shares:89.14M
Volume Ratio:0.50
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2288
EPS(LYR):-0.3117
ROE:-730.06%
ROA:-148.34%
PB:-0.90
PE(LYR):-0.81

Loading ...

VolitionRx Faces NYSE American Non-Compliance Notice Over Equity Requirements

Reuters
·
11 hours ago

VolitionRX Receives Notice of Non-Compliance With Nyse American Continued Listing Standards

THOMSON REUTERS
·
11 hours ago

VolitionRx Unveils Clinical Study Showing Nu.Q NETs Blood Test Guides Hidradenitis Suppurativa Treatment

Reuters
·
Feb 04

VolitionRX Limited Announces the Preparation of Reimbursement Submission for Its Nu.q® Cancer Assays

THOMSON REUTERS
·
Jan 30

VolitionRX Ltd: Once Reimbursement Achieved Anticipate Introduction of Nu.q Into Routine Clinical Use in France by Q4, 2026

THOMSON REUTERS
·
Jan 30

VolitionRx Unveils Study Supporting Nu.Q NETs Blood Test for Hidradenitis Suppurativa Management

Reuters
·
Jan 28

Volition Announces Data to Support Use of Nu.q® Nets in New Indication

THOMSON REUTERS
·
Jan 27

VolitionRX Ltd. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Jan 27

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 21

VolitionRX Expands Nu.Q Vet Cancer Test Access With New Laboratory Providers

Reuters
·
Jan 20

VolitionRX Ltd. Showcases Nu.Q Vet Cancer Test at VMX Veterinary Conference

Reuters
·
Jan 16

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 09

BRIEF-Volitionrx Ltd Enters Amended Securities Purchase Agreement

Reuters
·
Jan 08

VolitionRX Ltd - Enters Amended Securities Purchase Agreement

THOMSON REUTERS
·
Jan 08

VolitionRX Ltd - to Receive $2,000,000 From Investor

THOMSON REUTERS
·
Jan 08

Press Release: VolitionRx Secures $2.0 Million in Funding

Dow Jones
·
Jan 08

VolitionRX Ltd. unveils corporate deck highlighting cancer and sepsis diagnostics, licensing strategy, and global commercialization plans

Reuters
·
Jan 08

VolitionRx Unveils Breakthrough Liquid Biopsy Test for Feline Cancer Detection

Reuters
·
Jan 08

VolitionRX Announces Breakthrough Clinical Data for Nu.q® Vet Cancer Test in Cats

THOMSON REUTERS
·
Jan 08

VolitionRX Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 18, 2025